ATEZOLIZUMAB for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 18 adverse event reports in the FDA FAERS database where ATEZOLIZUMAB was used for Diffuse large b-cell lymphoma refractory.
Most Reported Side Effects for ATEZOLIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 3,591 | 10.7% | 3,591 | 457 |
| Off label use | 2,340 | 6.9% | 769 | 611 |
| Disease progression | 1,828 | 5.4% | 815 | 355 |
| Pyrexia | 1,599 | 4.7% | 261 | 1,096 |
| Diarrhoea | 1,490 | 4.4% | 327 | 798 |
| Fatigue | 1,253 | 3.7% | 296 | 504 |
| Anaemia | 1,195 | 3.6% | 237 | 695 |
| Pneumonia | 1,036 | 3.1% | 382 | 698 |
| Nausea | 953 | 2.8% | 219 | 498 |
| Dyspnoea | 938 | 2.8% | 290 | 614 |
| Decreased appetite | 928 | 2.8% | 233 | 436 |
| Hypothyroidism | 881 | 2.6% | 114 | 202 |
| Febrile neutropenia | 872 | 2.6% | 148 | 641 |
| Pneumonitis | 842 | 2.5% | 243 | 416 |
| Asthenia | 821 | 2.4% | 262 | 389 |
Other Indications for ATEZOLIZUMAB
Hepatocellular carcinoma (8,443)
Non-small cell lung cancer (4,459)
Small cell lung cancer (2,107)
Product used for unknown indication (1,888)
Small cell lung cancer extensive stage (1,398)
Triple negative breast cancer (1,393)
Lung neoplasm malignant (1,262)
Lung adenocarcinoma (1,032)
Non-small cell lung cancer metastatic (870)
Transitional cell carcinoma (788)
Other Drugs Used for Diffuse large b-cell lymphoma refractory
RITUXIMAB (667)
EPCORITAMAB-BYSP (353)
AXICABTAGENE CILOLEUCEL (336)
BENDAMUSTINE (283)
CYCLOPHOSPHAMIDE (226)
POLATUZUMAB VEDOTIN (223)
ETOPOSIDE (165)
POLATUZUMAB VEDOTIN-PIIQ (158)
GEMCITABINE (147)
LENALIDOMIDE (143)